<DOC>
	<DOCNO>NCT00456885</DOCNO>
	<brief_summary>This study look effect exenatide , drug approve treatment type 2 diabetes , body weight , appetite energy expenditure among moderately obese woman without diabetes . The study 35 week long include 19 outpatient visit . Participants receive exenatide 16 week placebo 16 week 3 week rest period . Neither participant investigator know whether exenatide placebo administer . Participants start randomly either exenatide placebo . Our hypothesis treatment exenatide curb appetite lead weight loss may lead change energy expenditure .</brief_summary>
	<brief_title>The Effect Exenatide Weight Hunger Obese , Healthy Women</brief_title>
	<detailed_description>This study examine effect exenatide body weight , energy expenditure , satiety , sleep , metabolic parameter healthy , moderately obese woman ( BMI 28-35 kg/m2 ) . We look 2 population woman , one normal glucose metabolism one impair glucose homeostasis ( IGH ) -- either impaired fasting glucose ( IFG , fast glucose 101-125 mg/dL ) impair glucose tolerance ( IGT , glucose 140-199 mg/dL 2h 75g oral glucose load ) . This randomized , double blind , crossover study two 16-week treatment period separate 3-week washout period . There 19 study visit 35 week . The goal study 1 ) examine effect exenatide body weight dysglycemia population medication study , namely obese woman without IGH 2 ) investigate possible mechanism weight loss measurement energy expenditure , hunger , satiety , nausea , sleep . The primary outcome study weight loss . We calculate absolute relative change body weight baseline week 16 ( first treatment period ) week 19 week 35 ( second treatment period ) . Body weight measure every study visit also allow u assess absolute relative change baseline throughout entire study .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Females age 2560 2 . BMI 2835 kg/m2 3 . No known diagnosis diabetes 4 . No known diagnosis coronary heart disease 5 . Selfdescribed sedentary lifestyle minimal regular cardiovascular exercise ( 1 hour per week ) 6 . Stable weight ( variation &lt; 3 kg within 6 month screen visit ) 7 . Ability give inform consent 8 . Ability follow verbal write instruction 9 . Use medically approve form contraception ( monophasic oral contraception , intra uterine device , surgical sterilization 2 combine barrier method ) 10 . Nonsmoker ( tobacco , marijuana ) 11 . Outpatient visit every 2 week throughout study period require . While visit short ( 15 minute ) ability commute performance site Boston , regular basis , necessary . 1 . Type 1 type 2 diabetes mellitus diagnose accord American Diabetes Association criteria 2 . Coronary heart disease ( history myocardial infarction unstable angina pectoris ) 3 . Uncontrolled hypertension hypertension ( BP &gt; 150/90 mmHg antihypertensive medication ) 4 . Uncontrolled dyslipidemia ( LDL &gt; 200 TG &gt; 400 lipid lower medication ) 5 . Tobacco , marijuana intravenous drug use 6 . Shift worker ( night shift alternate day/night shift ) 7 . Recent weight loss ( &gt; 3 kg within 4 month screen visit ) 8 . Gastroparesis 9 . Inflammatory bowel disease 10 . Malignancy treat chemotherapy within past 3 year 11 . History pancreatitis 12 . Depression require hospitalization diagnosis psychosis 13 . Renal insufficiency ( creatinine clearance &lt; 50 ml/min ) 14 . Transaminases &gt; 2x normal range 15 . Pregnancy within 6 month screen visit 16 . Breastfeeding 17 . Failure use medically approve contraceptive method 18 . History eat disorder ( anorexia , bulimia laxative abuse ) 19 . History surgery treatment obesity ( gastric banding , gastric bypass , gastric stapling ) 20 . New diagnosis hypo hyperthyroidism within 1 year screen visit 21 . Previous participation clinical study exenatide 22 . Presence history allergic reaction multiple drug</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>obesity</keyword>
	<keyword>double blind</keyword>
	<keyword>placebo control</keyword>
	<keyword>weight loss</keyword>
	<keyword>appetite</keyword>
	<keyword>energy expenditure</keyword>
</DOC>